Ketamine Clinical Trials
PET Imaging of mGluR5 With Drug Challenge
To see complete record on clinicaltrials.gov, please visit this link
Organisation Name: Yale University
Overal Status: Completed
Start Date: June 2012
Last Update: April 21, 2017
Lead Sponsor: Yale University
Brief Summary: This study is designed to look at that involvement of a process in the brain called the glutamate system in depression. Participants will undergo a screening session, up to two functional Magnetic Resonance Imaging (fMRI) scans, and up to three Positron Emission Tomography (PET) scans, as well as cognitive testing at each scan session. For one of the PET scans, a drug (either ketamine or n-acetyl cysteine) will be administered.Conditions
Hypothesis 1: The investigators hypothesize administration of ketamine or n-acetylcysteine (NAC) will lead to a decrease in mGluR5.
Hypothesis 2: The investigators hypothesize an improvement in memory and attentional skills after drug challenge.
Hypothesis 3: The investigators hypothesize an increase in mGluR5 availability and change in MRI measures post drug challenge as compared to baseline, signifying synaptogenesis.
Hypothesis 4: We expect there should not be a significant difference in reduction in mGluR5 availability due to differences in ABP688 radiotracer infusion.
- Major Depressive Disorder
- Post-Traumatic Stress Disorder (PTSD)
Total execution time in seconds: 0.15874195098877